Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Progression-free Survival
74%
Immune Checkpoint Inhibitor Therapy
62%
Immune Checkpoint Inhibitors
44%
Monotherapy
42%
Small Cell Lung Cancer
42%
Patient Characteristics
35%
Timing of Provision
35%
Non-squamous
35%
Do-not-resuscitate Orders
35%
Inhibitor Therapy
35%
Squamous Cell
35%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
35%
Irinotecan
35%
PD-1 Inhibitor
35%
Clinical Parameters
35%
Lung Cancer
24%
UGT1A1
23%
Programmed Death-ligand 1 Expression
23%
Immune-related Adverse Events
21%
Anticancer Treatment
21%
Clinical Practice
19%
Chromosomal Abnormalities
17%
Chemoimmunotherapy
17%
Platinum-based Chemotherapy
17%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
17%
Epidermal Growth Factor Receptor
17%
Pulmonary Sarcomatoid Carcinoma
17%
Pure Red Cell Aplasia
17%
Anemia
17%
Lung Adenocarcinoma
17%
Memory CD4+ T Cells
17%
Osimertinib
17%
Confidence Interval
14%
Survival Duration
14%
Median Overall Survival
12%
Tumor
12%
Systemic Immune Response
12%
Adverse Events
12%
Performance Status
11%
Pembrolizumab
10%
Cytotoxic Agents
10%
Durvalumab
10%
ALK Fusion Gene
10%
MET Exon 14
10%
Further Treatment
10%
Chemoradiation
10%
Combined Therapy
9%
Overall Survival
9%
Overall Survival Rate
9%
Pharmacology, Toxicology and Pharmaceutical Science
Progression Free Survival
79%
Immune Checkpoint Inhibitor
70%
Non Small Cell Lung Cancer
57%
Small Cell Lung Cancer
52%
Overall Survival
40%
Monotherapy
37%
Irinotecan
35%
Chemotherapy
26%
Adverse Event
25%
Programmed Death 1 Ligand 1
24%
Epidermal Growth Factor Receptor
23%
Disease
17%
Lung Cancer
17%
Epidermal Growth Factor Receptor Kinase Inhibitor
17%
Osimertinib
17%
Sarcomatoid Carcinoma
17%
Observational Study
12%
C Reactive Protein
11%
Recurrent Disease
11%
Neoplasm
11%
Survival Rate
10%
Durvalumab
8%
Chemoradiation Therapy
8%
Lactate Dehydrogenase
7%
Malignant Neoplasm
5%
Cytotoxic Agent
5%
Flow Cytometry
5%
Medicine and Dentistry
Immune Checkpoint Inhibitor
52%
Non Small Cell Lung Cancer
42%
Resuscitation
35%
Patient Characteristics
35%
Lung Cancer
35%
Overall Survival
17%
Chemoimmunotherapy
17%
Anemia
17%
Pure Red Cell Aplasia
17%
Chemotherapy
17%
Memory T Cell
17%
Chromosome Aberration
17%
Lung Adenocarcinoma
17%
Progression Free Survival
13%
Neoplasm
12%
Pembrolizumab
10%
T-Helper Cell
10%
Cytotoxic Agent
9%
Combined Therapy
9%
Immunity
8%
Prednisolone
8%
Small Cell Lung Cancer
7%
Gene Mutation
7%
Tumor Histology
7%
Systemic Therapy
7%
Adverse Event
6%
Survival Rate
6%
Flow Cytometry
5%
Programmed Death 1 Ligand 1
5%
